Sanofis

Investing.com — Shares of Cytokinetics (NASDAQ:), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ:) will acquire exclusive rights to develop and commercialize aficamten in Greater China, a move that underscores the drug’s potential in treating hypertrophic cardiomyopathy (HCM). The announcement reflects a strategic shift, as Sanofi takes…